United States · Telehealth platform · Compounded
Ivím Health review
Compounded semaglutide from $149/month plus a $74.99 membership, and one of the few to confirm HSA/FSA cards work.
Overview
Ivím sells compounded semaglutide “starting at $149/mo” with a separate membership at “$74.99/month,” putting realistic entry cost around $224/month. The membership is described as covering unlimited 1:1 provider consults, 24/7 care-team access, functional nutritional counselling, community support and app access.
It is straightforward about the regulatory position, stating that “semaglutide is presently only available as prescription brand name products, Wegovy and Ozempic” — an unusually clear acknowledgement on a page selling the compounded version. It also states plainly that “compounded semaglutide medication is not covered by insurance.”
The one payment detail it does confirm, which most competitors leave unanswered, is HSA/FSA: “Yes! Compounded semaglutide medication can be paid for with your HSA or FSA card.” Against that, lab requirements, shipping and cancellation terms are all absent from the page.
Medications and supply
Compounded. Ivím states semaglutide is presently only available as the brand-name products Wegovy and Ozempic, and that compounded versions are not FDA-approved.
- Compounded semaglutide
How the service works
- Consultation
- Medical questionnaire, then “your Ivím medical provider will evaluate your eligibility… and discuss your medication options.”
- Eligibility
- Evaluated by an Ivím medical provider from the questionnaire.
- Provider involvement
- Unlimited 1:1 provider consults and 24/7 access to a care team, inside the membership.
- Lab requirements
- Not stated in the sources we checked.
- Pharmacy fulfilment
- Not stated in the sources we checked.
- Shipping
- Not stated in the sources we checked.
- Support services
- Unlimited provider consults, 24/7 care team, functional nutritional counselling, community support, mobile app.
What it costs
| Item | Published price | Notes |
|---|---|---|
| Compounded semaglutide | from $149 / month | — |
| Membership | $74.99 / month | separate from medication |
- Membership fee
- $74.99 per month.
- Medication fee
- From $149/month, billed separately.
- Insurance
- None for the medication — Ivím states compounded semaglutide is not covered by insurance.
- HSA / FSA
- Confirmed. Ivím states compounded semaglutide can be paid for with an HSA or FSA card.
- Cancellation
- Not stated in the sources we checked.
- Refunds
- Not stated in the sources we checked.
Pros
- Confirms HSA/FSA eligibility outright, which most competitors do not address
- Unlimited provider consults and 24/7 care-team access in the membership
- Honest on its own sales page that compounded semaglutide is not the approved product
- Nutrition counselling included rather than upsold
Cons
- Two separate charges — the $149 headline understates the real cost by $74.99
- Semaglutide only; no tirzepatide option listed
- No lab, shipping, or cancellation information published
- Not covered by insurance, by its own statement
Who it may suit
Someone paying with an HSA or FSA card who wants compounded semaglutide with substantial included clinical contact.
Limitations
- Compounded products are not FDA-approved
- Single-molecule offering
- Plan length and lock-in terms are not stated
Questions
Can I pay with an HSA or FSA card?
Ivím states yes — compounded semaglutide medication can be paid for with an HSA or FSA card. It is one of the few services in this set to answer that question directly.
What is the real monthly cost?
The $149 medication price plus the $74.99 membership, so roughly $224/month at the entry dose.
Does insurance cover it?
No. Ivím states compounded semaglutide medication is not covered by insurance.
Sources
Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.
- 01Ivím Health — compounded semaglutide (pricing, membership, HSA/FSA, insurance)retrieved 2026-08-14